Published in Cephalalgia on September 01, 1999
Efficacy of 5HT in migraine. Cephalalgia (1999) 0.75
Antineuropathic effect of 7-hydroxy-3,4-dihydrocadalin in streptozotocin-induced diabetic rodents. BMC Complement Altern Med (2014) 0.75
Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess (2004) 29.45
Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature (1995) 4.24
Midwife managed delivery unit: a randomised controlled comparison with consultant led care. BMJ (1994) 4.23
Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A (2001) 3.23
Oral sumatriptan in acute migraine. Lancet (1991) 2.87
Paying general practitioners: shedding light on the review of health services. J R Coll Gen Pract (1989) 2.83
An economic view of high compliance as a screening objective. BMJ (1994) 2.56
The future of health care in Canada. BMJ (2001) 2.53
Are cost of injury studies useful? Inj Prev (2000) 2.50
Recruitment methods for screening programmes: trial of a new method within a regional osteoporosis study. BMJ (1992) 2.27
Amnestic people with Alzheimer's disease who remembered the Kobe earthquake. Br J Psychiatry (1998) 2.26
Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci U S A (1994) 2.14
Assessing the costs of assisted reproductive techniques. Br J Obstet Gynaecol (1996) 2.07
The cost of cervical cancer screening provided by a women's health nurse. Aust J Public Health (1992) 1.94
Rfc5, a small subunit of replication factor C complex, couples DNA replication and mitosis in budding yeast. Proc Natl Acad Sci U S A (1996) 1.89
Chiropody and the QALY: a case study in assigning categories of disability and distress to patients. Health Policy (1991) 1.89
Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci U S A (1995) 1.86
Effectiveness of cognitive-behavioural family intervention in reducing the burden of care in carers of patients with Alzheimer's disease. Br J Psychiatry (2000) 1.81
Rfc5, a replication factor C component, is required for regulation of Rad53 protein kinase in the yeast checkpoint pathway. Mol Cell Biol (1997) 1.77
Ophthalmoplegic migraine: a recurrent demyelinating neuropathy? Cephalalgia (2001) 1.77
Clinical features of symptomatic Rathke's cleft cyst. Clin Neurol Neurosurg (2001) 1.68
A social skills group for boys with Asperger's syndrome. Aust N Z J Psychiatry (1995) 1.66
Effect of cortical spreading depression on activity of trigeminovascular sensory neurons. Cephalalgia (1999) 1.58
Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem (1993) 1.57
Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med (1998) 1.55
Do the Y-set and double-bag systems reduce the incidence of CAPD peritonitis? A systematic review of randomized controlled trials. Nephrol Dial Transplant (2001) 1.55
Age-restricted cervical screening: HPV testing at age 50 identifies a high risk group for cervical disease. Int J Gynecol Cancer (2002) 1.55
Rfc5, in cooperation with rad24, controls DNA damage checkpoints throughout the cell cycle in Saccharomyces cerevisiae. Mol Cell Biol (2000) 1.54
Rapid resolution of symptomatic acute subdural hematoma: case report. Surg Neurol (1997) 1.53
The Southern Alberta Renal Program database: a prototype for patient management and research initiatives. Clin Invest Med (2001) 1.52
Tools of the trade: a comparative analysis of approaches to priority setting in healthcare. Health Serv Manage Res (2003) 1.51
Should QALYs be programme-specific? J Health Econ (1988) 1.51
Formation of cholesterol- and apoprotein E-enriched high density lipoproteins in vitro. J Biol Chem (1983) 1.50
Mechanisms of oral-pharyngeal dysphagia in patients with Parkinson's disease. Gastroenterology (1996) 1.49
Recruitment methods for screening programmes: trial of an improved method within a regional osteoporosis study. BMJ (1993) 1.49
Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev (2001) 1.48
The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. Neurology (2004) 1.45
Point mutation in platelet mitochondrial tRNA(Leu(UUR)) in patient with cluster headache. Lancet (1994) 1.45
Hormone replacement therapy: compliance and cost after screening for osteoporosis. Eur J Obstet Gynecol Reprod Biol (1995) 1.45
Twenty-five years of programme budgeting and marginal analysis in the health sector, 1974-1999. J Health Serv Res Policy (2001) 1.44
Double bag or Y-set versus standard transfer systems for continuous ambulatory peritoneal dialysis in end-stage renal disease. Cochrane Database Syst Rev (2001) 1.44
Teaching physical diagnosis in the nursing home: a prospective, controlled trial. J Am Geriatr Soc (1991) 1.43
Acute subdural hematomas due to rupture of cortical arteries: a study of the points of rupture in 19 cases. Surg Neurol (1997) 1.43
Utilisation as a measure of equity: weighing heat? J Health Econ (1991) 1.43
Multiple myeloma: the bone marrow microenvironment and its relation to treatment. Br J Biomed Sci (2013) 1.42
Using economics to prioritize research: a case study of randomized trials for the prevention of hip fractures due to osteoporosis. J Health Serv Res Policy (1996) 1.41
Creativity and sacrifice: two sides of the coin. A reply to David Seedhouse. Health Care Anal (1997) 1.40
Bone mineral density measurements: are they worth while? J R Soc Med (1996) 1.39
Light chain restriction analysis of bone marrow plasma cells in patients with MGUS or 'solitary' plasmacytoma: diagnostic value and correlation with clinical course. Br J Haematol (1990) 1.39
A herb for migraine. Nurs Times (2002) 1.38
An economic evaluation of early versus late referral of patients with progressive renal insufficiency. Am J Kidney Dis (2001) 1.36
Caveat emptor or blissful ignorance? Patients and the consumerist ethos. Soc Sci Med (1991) 1.35
Growth stimulation of human diploid fibro-blasts by the tumor promoter, 12-0-tetradecanoly-phorbol-13-acetate. Int J Cancer (1974) 1.33
Using economics alongside clinical trials: why we cannot choose the evaluation technique in advance. Health Econ (1996) 1.32
Phosphorylation of xanthine dehydrogenase/oxidase in hypoxia. J Biol Chem (2001) 1.27
Neural basis of the emotional Stroop interference effect in major depression. Psychol Med (2007) 1.26
Secondary glaucoma after paediatric cataract surgery. Br J Ophthalmol (2007) 1.25
HIV infection and AIDS in England and Wales: general practitioners' workload and contact with patients. Br J Gen Pract (1990) 1.25
Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J Biol Chem (1997) 1.24
Day hospitals for the elderly: utilisation and performance. Community Med (1987) 1.23
Clinical determinants of dementia and mild cognitive impairment following ischaemic stroke: the Sydney Stroke Study. Dement Geriatr Cogn Disord (2006) 1.22
Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project. Health Technol Assess (2010) 1.22
Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J Histochem Cytochem (1999) 1.22
Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important determinants? Clin Nephrol (2003) 1.21
Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol (2000) 1.20
Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache (1991) 1.17
Helicopters, hearts and hips: using willingness to pay to set priorities for public sector health care programmes. Soc Sci Med (1998) 1.17
Proteolytic activation of hepatocyte growth factor in response to tissue injury. J Biol Chem (1994) 1.15
Tobacco mosaic virus multiplication and expression of the N gene in necrotic responding tobacco varieties. Virology (1972) 1.14
Premorbid brain size as a determinant of reserve capacity against intellectual decline in Alzheimer's disease. Am J Psychiatry (1997) 1.14
Health economic evaluation. J Epidemiol Community Health (2002) 1.13
Prospective evaluation of somatic and autonomic small fibers in selected autonomic neuropathies. Neurology (2004) 1.12
Economics, public health and health care purchasing: the Tayside experience of programme budgeting and marginal analysis. J Health Serv Res Policy (1996) 1.11
The cost of diabetes. Diabet Med (1989) 1.11
Applications of cost-benefit analysis to health care. Departures from welfare economic theory. J Health Econ (1987) 1.11
An evidence synthesis of qualitative and quantitative research on component intervention techniques, effectiveness, cost-effectiveness, equity and acceptability of different versions of health-related lifestyle advisor role in improving health. Health Technol Assess (2011) 1.11
Frontal lobe hypometabolism and depression in Alzheimer's disease. Neurology (1998) 1.10
Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science. Pharmacoeconomics (1999) 1.10
Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology (1998) 1.09
Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev (2005) 1.09
Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosci Lett (1997) 1.06
Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem (2000) 1.06
Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J Anat (1999) 1.04
Population screening for low bone mineral density: do non-attenders have a lower risk of osteoporosis? Osteoporos Int (1994) 1.04
Programme budgeting and marginal analysis: a case study of maternity services. J Public Health Med (1996) 1.02
Amygdalar volume and emotional memory in Alzheimer's disease. Am J Psychiatry (1999) 1.02
Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J Biol Chem (1996) 1.02
Lack of association of apolipoprotein E epsilon4 allele dose with cerebral glucose metabolism in Alzheimer disease. Alzheimer Dis Assoc Disord (1998) 1.01
Hypofunction in the posterior cingulate gyrus correlates with disorientation for time and place in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1998) 1.01
Specific high-affinity binding and biologic action of retinoic acid in human neuroblastoma cell lines. Proc Natl Acad Sci U S A (1983) 0.99
Cloning and characterization of the gene encoding the human platelet glycoprotein V. A member of the leucine-rich glycoprotein family cleaved during thrombin-induced platelet activation. J Biol Chem (1993) 0.98
Private versus social opportunity cost of time: valuing time in the demand for health care. Health Econ (1994) 0.98
Consumerism in the health care setting: an exploratory study of factors underlying the selection and evaluation of primary medical services. Aust J Public Health (1991) 0.96
Purkinje cell antibody in lupus ataxia. Lancet (1993) 0.95
Factors associated with psychotic symptoms in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1998) 0.95
Reweighing heat: response to Culyer, van Doorslaer and Wagstaff. J Health Econ (1992) 0.95
Anxiety traits associated with a polymorphism in the serotonin transporter gene regulatory region in the Japanese. J Hum Genet (1999) 0.95